Ilyeon Pharmaceutical Decides on 80 Billion KRW Paid-in Capital Increase and Convertible Bond Issuance
[Asia Economy Reporter Minji Lee] Ilyeon Pharmaceutical announced that it has decided to issue the 2nd series of bearer, detachable warrant, unsecured private convertible bonds to raise facility funds. The total face value of the bonds is 70 billion KRW, with both the nominal interest rate and maturity interest rate set at 0%.
Hot Picks Today
"With This Certificate, Even Those in Their 60s...
- Popcorn Container Craze at Theaters Sparks Sell-Out Frenzy, Emerges as New Reven...
- When His Father Suddenly Collapsed Before His Eyes... 13-Year-Old Son Preserves ...
- "Six Months After 'Mom's Touch Troublesome Woman' Incident... Franchise Says, 'S...
- "Quit Office Job to Earn Over 200 Million Won a Year"… Chinese Woman in Her 30s...
Additionally, it plans to raise 10 billion KRW in facility funds through a paid-in capital increase. The allottee is Quad Asset Management.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.